JNJ-26483327

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameJNJ-26483327
Drug Alias NameJNJ-26483327MTKi-327BGB-102
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsVascular endothelial growth factor receptor inhibitorsSRC inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Vascular endothelial growth factor receptorSRC +[5] 
Therapy Area/IndicationsSolid tumoursMacular DegenerationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines LtdGraybug Vision Inc
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLCJanssen Pharmaceutical Nv
Active IndicationsMacular Degeneration
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A